Previous Article | Next Article 
Molecular and Cellular Biology, April 1999, p. 2863-2871, Vol. 19, No. 4
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Tat Activates Human Immunodeficiency Virus Type 1 Transcriptional
Elongation Independent of TFIIH Kinase
Dan
Chen and
Qiang
Zhou*
Department of Molecular and Cell Biology,
University of California at Berkeley, Berkeley, California 94720
Received 11 September 1998/Returned for modification 13 October
1998/Accepted 15 December 1998
 |
ABSTRACT |
Tat stimulates human immunodeficiency virus type 1 (HIV-1)
transcriptional elongation by recruitment of the human transcription elongation factor P-TEFb, consisting of Cdk9 and cyclin T1, to the
HIV-1 promoter via cooperative binding to the nascent HIV-1 transactivation response RNA element. The Cdk9 kinase activity has been
shown to be essential for P-TEFb to hyperphosphorylate the
carboxy-terminal domain (CTD) of RNA polymerase II and mediate Tat
transactivation. Recent reports have shown that Tat can also interact
with the multisubunit transcription factor TFIIH complex and increase
the phosphorylation of CTD by the Cdk-activating kinase (CAK) complex
associated with the core TFIIH. These observations have led to the
proposal that TFIIH and P-TEFb may act sequentially and in a concerted
manner to promote phosphorylation of CTD and increase polymerase
processivity. Here, we show that under conditions in which a specific
and efficient interaction between Tat and P-TEFb is observed, only a
weak interaction between Tat and TFIIH that is independent of critical
amino acid residues in the Tat transactivation domain can be detected.
Furthermore, immunodepletion of CAK under high-salt conditions, which
allow CAK to be dissociated from core-TFIIH, has no effect on either
basal HIV-1 transcription or Tat activation of polymerase elongation in
vitro. Therefore, unlike the P-TEFb kinase activity that is essential
for Tat activation of HIV-1 transcriptional elongation, the CAK kinase
associated with TFIIH appears to be dispensable for Tat function.
 |
INTRODUCTION |
Human immunodeficiency virus type 1 (HIV-1) encodes a small regulatory protein, Tat, which strongly
stimulates HIV-1 transcriptional elongation by interacting with the
transactivation response (TAR) RNA stem-loop structure located at the
5' end of the nascent viral transcripts (12, 13). A protein
phosphorylation event which can be inhibited by specific kinase
inhibitors has been recognized as a key step in Tat transactivation
(21, 22). It has been shown that hyperphosphorylation of the
carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase
II correlates closely with the production of highly processive
polymerase elongation complexes (7) and that Tat activation
of HIV-1 elongation requires CTD (5, 26, 28, 39). Based on
these observations, it has been proposed that Tat activation is
mediated by a cellular kinase, whose phosphorylation of CTD and perhaps
other components of the polymerase elongation complex is essential for
the generation of highly processive polymerase elongation complexes
(12, 40).
Among many cellular kinases that are capable of phosphorylating pol II
CTD in vitro, two Cdk-cyclin pairs present in two transcription factor
complexes have been implicated as Tat coactivators to facilitate Tat
stimulation of polymerase elongation. The first one, a Cdk9-cyclin T1
pair, was recently found to constitute the human positive-acting transcription elongation factor P-TEFb, and it can support both basal
transcriptional elongation (32) as well as Tat activation (4, 27). P-TEFb was first identified and purified from
Drosophila extracts (24), and it functions by
hyperphosphorylating pol II CTD and preventing polymerase arrest
(23). Immunodepletion of Cdk9 from HeLa nuclear extract
eliminated basal HIV-1 transcription elongation and Tat transactivation
(21, 42, 45), and the addition of affinity-purified human
P-TEFb complex completely restored these two processes (42).
Human P-TEFb was shown to interact with the activation domain of Tat
(11, 45), suggesting that it may be a direct target of Tat.
In fact, Tat was recently found to stimulate polymerase elongation by
recruitment of the P-TEFb complex to the HIV-1 promoter through a
Tat-TAR interaction (4, 42). In addition to forming a
complex with Tat, P-TEFb was also found to interact with and
phosphorylate Tat-SF1, a transcription elongation factor required for
Tat transactivation (16, 42). Recently, a novel cyclin
C-related protein called cyclin T1 has been shown to be a major partner
of Cdk9 in human cells (32, 38). Importantly, Wei et al.
(38) have demonstrated that recombinant cyclin T1 interacted
specifically with the transactivation domain of Tat and that this
association mediated the high-affinity binding of the Tat-cyclin T1
complex to TAR RNA dependent on sequences in the TAR apical loop.
In addition to the Cdk9-cyclin T1 dimer that constitutes the P-TEFb
complex, recent studies have also implicated TFIIH as a Tat-specific
coactivator. TFIIH is comprised of nine polypeptides (ERCC3, ERCC2,
p62, p54, p44, Cdk7, cyclin H, Mat1, and p34) and has dual roles in
transcriptional regulation and DNA repair (for a review see reference
20). In transcription reactions, TFIIH is part of
the preinitiation complex and functions at the stages of initiation and
promoter clearance when the RNA transcript is less than 30 to 50 bases
long (41). This is in contrast to P-TEFb, which does not
associate with the preinitiation complex and works at the stage of RNA
chain elongation after the polymerase clears the promoter
(14).
TFIIH has a kinase activity, and this activity resides in the Cdk7
subunit, which interacts with cyclin H and Mat1 to form a stable
trimeric Cdk-activating kinase (CAK) complex. CAK has been shown to
exist in three distinct complexes (20, 37). While the
majority is present as free CAK, it was also found to exist as a
CAK-ERCC2 complex as well as in association with the core TFIIH (ERCC3,
ERCC2, p62, p54, p44, and p34) to form the holo-TFIIH complex. In
addition to having a role in cell cycle control, CAK has been widely
postulated to function as a major CTD kinase in transcription reactions
(2, 37), leading several groups to examine whether Tat may
target TFIIH-CAK directly. In fact, Tat has been shown to interact with
TFIIH and to stimulate phosphorylation of pol II CTD by the TFIIH
kinase, although different groups have different opinions on which
subunit of TFIIH mediates Tat binding (3, 6, 9, 28).
Recently, Cujec et al. (6) showed that Tat binds directly to
Cdk7 and that Tat activation can be blocked by a Cdk7
pseudosubstrate peptide inhibitor. Based on these results,
a two-stage model for CTD phosphorylation, suggesting that both TFIIH
and P-TEFb act sequentially and in a concerted manner to promote
hyperphosphorylation of CTD and increase polymerase processivity, has
been proposed (12, 40).
Because two distinct Cdk-cyclin pairs have been demonstrated to be
coactivators of Tat by different groups under different experimental
conditions, we decided to investigate their roles in Tat
transactivation under the same condition. Our data indicate that while
the human P-TEFb complex is essential for Tat transactivation, neither
free CAK nor CAK associated with core-TFIIH seems to be required for
Tat function in vitro. Correlating with their roles in transcription
reactions, we show here that under the same condition where a specific
and efficient interaction between P-TEFb and Tat is observed, only weak
interactions between Tat and CAK and between Tat and core-TFIIH that
are independent of several critical amino acid residues in the Tat
transactivation domain can be detected. These results further
underscore the importance of P-TEFb in Tat transactivation and also
reveal that the CAK kinase complex associated with TFIIH is dispensable
for Tat function in vitro.
 |
MATERIALS AND METHODS |
Antibodies.
Commercial preparations of rabbit polyclonal
antibodies directed against Cdk7, Mat1, and ERCC3 were obtained from
Santa Cruz Biotechnology (Santa Cruz, Calif.). The anti-cyclin H
antiserum was raised in rabbits. Anti-Cdk7 and anti-Mat1 polyclonal
antibodies or monoclonal antibody (MAb) 12CA5 recognizing the
hemagglutinin (HA) epitope tag was directly coupled to protein
A-Sepharose with dimethylpimelimidate as described previously
(10).
Immunoaffinity-purification of Cdk7-HA and associated
proteins.
Thirty micrograms of HA-tagged Cdk7 construct
(6) was transfected into human 293T cells by the calcium
phosphate precipitation method. Forty-eight hours posttransfection,
cells were washed in phosphate-buffered saline and lysed with either
high-salt lysis buffer (500 mM NaCl, 1% Nonidet P-40 [NP-40], 50 mM
HEPES-KOH [pH 7.9], 0.5 mM EDTA, 2 mM dithiothreitol [DTT], and 0.5 mM phenylmethylsulfonyl fluoride [PMSF]) or low-salt lysis buffer
(150 mM NaCl, 1% NP-40, 50 mM HEPES-KOH [pH 7.9], 0.5 mM EDTA, 2 mM
DTT, and 0.5 mM PMSF), as specified in the text and figure legend.
Precleared cell lysates were subjected to immunoprecipitation with
immobilized MAb 12CA5 under the same buffer conditions as for cell
lysis. After extensive washes, Cdk7-HA-containing complexes were eluted
from the antibody column with the elution solution containing 1 mg of
HA epitope peptide/ml as described previously (43).
Immunodepletion of Cdk7 or Mat1 from HeLa nuclear extract.
Immunodepletion was carried out by incubating HeLa nuclear extract
containing 0.15% NP-40 and either 0.1 M or 0.8 M KCl with anti-Cdk7 or
anti-Mat1 antibodies immobilized on protein A-Sepharose. Incubation was
carried out at 4°C for 1 h, and the supernatant was incubated
with fresh antibody beads two more times. The depleted extracts were
subjected to spin column (Sephadex G-25) desalting prior to analysis in
transcription reactions.
Tat binding assays.
Cdk9-HA and its associated proteins
(labeled P-TEFb fraction) were affinity-purified from a stable human
293-derived cell line (B4) expressing Cdk9-HA as previously described
(42). Cdk7-HA and associated proteins (labeled TFIIH
fraction) were affinity-purified as described above. These two
fractions were incubated with wild-type GST-Tat(1-48), mutant
GST-Tat(1-48, C22G), GST-Tat(1-48, K41A), GST-Tat(1-48, H33A), or
glutathione S-transferase (GST) bound to
glutathione-Sepharose at 23°C for 20 min. The binding buffer contains
20 mM Tris-HCl (pH 8.0), 20% glycerol, 500 mM KCl, 0.5% NP-40, 0.05%
sodium dodecyl sulfate (SDS), 0.2 mM EDTA, 0.2 mg of bovine serum
albumin/ml, 0.2 mM ZnCl2, 1 mM DTT, and 0.5 mM PMSF. After
extensive washes in the same buffer, the bound proteins were analyzed
by SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotting.
Transcription assay.
In vitro transcription reactions
containing HeLa nuclear extract and HIV-1 promoter templates were
carried out as previously described (28, 44). G-less RNA
fragments derived from HIV transcripts were isolated after RNase T1
treatment and analyzed on 6% sequencing gels.
 |
RESULTS |
P-TEFb, but not TFIIH, interacts with Tat specifically and
efficiently.
HIV-1 Tat has been shown to interact with TFIIH
(3, 6, 9, 28) and P-TEFb (11, 45) in different
reports following different protocols. We decided to compare the
efficiency and specificity of these interactions under exactly the same
conditions. CAK and its associated core-TFIIH in the holo-TFIIH complex
were purified from human 293T cells expressing an HA-tagged Cdk7
(Cdk7-HA) by immunoprecipitation with MAb 12CA5 followed by elution
with HA epitope peptide (42, 43). The affinity-purified
complex was shown by Western blotting to contain Cdk7, Mat1 (Fig.
1C), and cyclin H (see Fig. 4), the three
subunits of CAK. It also contained ERCC3 (Fig. 1C), one of the
core-TFIIH subunits. A similar procedure was used to obtain
affinity-purified P-TEFb complex from a stable human 293 cell line (B4)
expressing HA-tagged Cdk9 (Cdk9-HA) (4, 27). In addition to
the Cdk9-HA-cyclin T1 heterodimer that constitutes the mature and
active form of P-TEFb and supports Tat transactivation, the
affinity-purified Cdk9-HA fraction also contained two other complexes
that consist of Cdk9-HA/Hsp90/Cdc37 and Cdk9-HA/Hsp70, which function
as precursors of the active P-TEFb complex (27). Because
both Cdk7-HA of TFIIH and Cdk9-HA of P-TEFb contained an HA tag,
Western blotting with MAb 12CA5 was used to normalize their levels in
Tat-binding reactions.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
Strong and specific binding of Tat to P-TEFb but not to
TFIIH. (A) Binding of P-TEFb to Tat. Affinity-purified P-TEFb complex
fraction (6 µl) was incubated with wild-type GST-Tat(1-48) and three
GST-Tat(1-48) mutants (C22G, K41A, and H33A) bound to
glutathione-Sepharose beads. After extensive washes, the bound proteins
were analyzed by SDS-PAGE and Western blotting for the presence of
cyclin T1 and Cdk9-HA with antibodies specific for cyclin T1 and HA
(MAb 12CA5), respectively. One microliter of the input P-TEFb fraction
was used in lane 1 as a reference. The lower panel is a
Coomassie-stained SDS gel showing the relative amounts of wild-type and
mutant GST-Tat(1-48) proteins bound to glutathione-Sepharose beads. (B)
Binding of TFIIH to Tat. TFIIH fraction (2 µl) with associated
Cdk7-HA at a level similar to that of Cdk9-HA in P-TEFb (6 µl) was
tested for binding to Tat under the same conditions as for P-TEFb.
After washes, Western blotting with 12CA5 was used to detect Cdk7-HA
bound to the GST-Tat beads. (C) Five times more TFIIH fraction (10 µl) was tested for binding to GST, wild-type, or mutant GST-Tat(1-48)
beads. Bound proteins were examined by Western blotting with antibodies
specific for ERCC3, the HA tag of Cdk7-HA, and Mat1.
|
|
When the Cdk9-HA fraction (labeled P-TEFb) was incubated with
immobilized wild-type GST-Tat(1-48) that lacks the RNA-binding C
terminus but contains an intact transactivation domain (11, 33), approximately 17% of Cdk9-HA and 60% of cyclin T1 present in the input fraction were found to bind to the Tat column (Fig. 1A).
The apparent difference between Cdk9-HA and cyclin T1 in Tat-binding
efficiency can be explained by our recent observation that among the
three Cdk9-HA complexes in the affinity-purified Cdk9-HA fraction,
only the Cdk9-HA-cyclin T1 dimer (P-TEFb) demonstrated high-affinity
interaction with Tat (27). Importantly, interaction of
P-TEFb with Tat was absolutely dependent on an intact Tat activation domain (Fig. 1A), as three point mutations (C22G, H33A, and K41A) that
are located in the Tat activation domain and were shown previously to
destroy Tat transactivation (33) also inhibited the
Tat-P-TEFb interaction.
When affinity-purified TFIIH fraction, which contained a similar amount
of Cdk7-HA as Cdk9-HA in the P-TEFb fraction, was tested for binding to
Tat, virtually no Cdk7-HA was found to associate with the GST-Tat
column (Fig. 1B, upper panel). When five times more TFIIH fraction was
used in the binding reactions, about 2% of Cdk7-HA, Mat1, and ERCC3
from the input fraction were found to bind to the wild-type
GST-Tat(1-48) column but not to a column with GST only (Fig. 1C).
However, unlike the interaction between Tat and P-TEFb, the weak
binding of TFIIH to Tat was not disrupted by any of the three point
mutations in the Tat activation domain (Fig. 1C). Thus, under the same
condition, where a specific and efficient interaction between Tat and
P-TEFb was observed, a much weaker interaction between Tat and TFIIH
that is insensitive to mutations of several critical amino acid
residues in the Tat activation domain was detected.
The binding condition used above contained a high salt concentration
(500 mM KCl) and detergents (0.5% NP-40 and 0.05% SDS), which may
prevent a specific interaction of CAK-TFIIH with Tat. To test this
possibility, we also examined the binding of TFIIH to Tat under less
stringent conditions in which an interaction between Tat and TFIIH was
previously observed (28). Moreover, we also varied the
concentration of GST-Tat on the beads in reactions containing 100 mM
KCl and no detergents. Under these mild conditions, CAK and core-TFIIH
were found to bind to GST-Tat readily, but these interactions were only
slightly affected by the C22G point mutation in the Tat activation
domain (data not shown). Therefore, neither the stringent nor the mild
salt conditions revealed a specific Tat-TFIIH interaction that is
dependent on the wild-type Tat activation domain.
Immunodepletion of Cdk7 at different salt concentrations has
different effects on Tat transactivation.
Human P-TEFb not only
bound tightly and specifically to the Tat activation domain, it was
also required for Tat activation of HIV-1 transcription in vitro
(Fig. 2A). Compared with mock-depleted HeLa nuclear extract, which supported a Tat-specific and
TAR-dependent activation of HIV-1 transcriptional elongation
(44) (Fig. 2A, left panel, lanes 1 and 2), immunodepletion
of Cdk9-P-TEFb from HeLa nuclear extract under high-salt conditions
(0.8 M KCl) eliminated HIV-1 transcription (Fig. 2A, lanes 3 and 4).
Importantly, the addition of affinity-purified human P-TEFb complex
into the depleted extract resulted in a complete recovery of both basal
and Tat-activated HIV-1 transcriptional elongation (lanes 5 and 6). To
determine whether P-TEFb is really a Tat-specific coactivator or simply a general elongation factor that plays a basic role during polymerase elongation, we recently generated and examined the activities of
human-rodent "hybrid" P-TEFb complexes (4). Our results indicated that human P-TEFb is both a basal elongation factor as well
as a Tat-specific coactivator and that these two activities can be
separated. Moreover, the specific interaction of human P-TEFb with Tat
at the HIV-1 TAR RNA element is crucial for P-TEFb to mediate a
Tat-specific and species-restricted activation of HIV-1 transcription
(4).


View larger version (44K):
[in this window]
[in a new window]
|
FIG. 2.
Tat transactivation in HeLa nuclear extract depleted of
Cdk7 or Cdk9. (A [left panel]) Transcription reactions containing
both templates pHIV+TAR-G400 and pHIV TAR-G100 were performed in the
absence ( ) or presence (+) of Tat and mock-depleted HeLa nuclear
extract (lanes 1 and 2) or HeLa nuclear extract immunodepleted of the
Cdk9 subunit of P-TEFb (lanes 3 to 6). Affinity-purified P-TEFb complex
was added to Cdk9-depleted reactions as indicated. Immunodepletion was
performed in the presence of 0.8 M KCl. (Right panel) The depleted
extracts were examined by Western blotting with Cdk9 antibodies. (B and
C) Cdk7, a subunit of the CAK ternary complex, was removed from HeLa
nuclear extract by immunodepletion with anti-Cdk7 antibodies under
high-salt (0.8 M KCl [B]) or low-salt (0.1 M KCl [C]) conditions.
Immobilized anti-Myc antibody was used in control depletion reactions.
(Left halves of panels B and C) Transcription reactions containing
depleted extracts and transcription templates were carried out in the
absence ( ) or presence (+) of Tat. (Right halves of panels B and C)
The depleted extracts were analyzed by Western blotting with anti-Cdk7
antibodies.
|
|
With the demonstration that Tat activation depends on P-TEFb and Tat
interacts specifically with P-TEFb but not with CAK or core-TFIIH, we
decided to investigate whether CAK of holo-TFIIH is actually required
for Tat activation of HIV-1 transcription. HeLa nuclear extract was
subjected to immunodepletion with anti-Cdk7 antibodies immobilized on
protein A-Sepharose beads at two different salt concentrations (0.8 M
and 0.1 M KCl). A column containing immobilized anti-Myc antibody was
used as a control. As indicated by Western analyses (right panels of
Fig. 2B and C), no detectable Cdk7 remained in HeLa nuclear extract
after anti-Cdk7 immunodepletion at both salt concentrations. Moreover,
Mat1, a subunit of the CAK ternary complex, was also removed from the
Cdk7-depleted extracts (data not shown), indicating that the anti-Cdk7
immunodepletion was able to remove both Cdk7 and its associated
proteins in the CAK ternary complex from HeLa nuclear extracts.
Next, the Cdk7-depleted extracts were analyzed in transcription
reactions for their abilities to mediate Tat activation (left panels of
Fig. 2B and C). Depending on the conditions of depletion, significant differences between the two Cdk7-depleted extracts in their
abilities to mediate basal HIV-1 transcription and Tat activation were
observed (Fig. 2B and C). In reactions containing HeLa nuclear extract
mock-depleted with the control anti-Myc column at either of the two
salt conditions, Tat specifically activated transcriptional elongation
from HIV-1 template containing wild-type TAR element
(pHIV+TAR-G400 [44]) but not from an
internal control template (pHIV
TAR-G100) with a mutant TAR (Fig. 2B
and C, lanes 1 and 2). Importantly, unlike anti-Cdk9
immunodepletion (Fig. 2A), removal of Cdk7-CAK from HeLa nuclear
extract under high-salt conditions (0.8 M KCl) did not have a
significant effect on either basal or Tat-activated HIV-1 transcription
compared with the mock-depleted reactions (Fig. 2B, left panel, lanes 1 and 2 showed 5.5-fold and lanes 3 and 4 showed 6.3-fold Tat activation
when normalized to internal controls). In contrast, immunodepletion of
Cdk7 in the presence of 0.1 M KCl significantly reduced basal
transcription and virtually eliminated Tat activation (Fig. 2C, left
panel). As discussed below, the low-level basal transcription produced by the depleted extract may derive from a minor form of transcription complex whose assembly on the HIV-1 long terminal repeat does not
require a TATA box, TFIIH, or a few other basal transcription factors (18, 29, 31). Together, these results suggest
that although Cdk7 can be immunodepleted efficiently from HeLa nuclear extract in the presence of either 0.1 or 0.8 M KCl, different forms of Cdk7 complexes were probably depleted under these two conditions. Proteins complexed with Cdk7 under mild salt
concentrations are most likely required for HIV-1 transcription.
Different sizes of Cdk7-containing complexes exist at different
salt concentrations.
To examine how different salt concentrations
used in the immunodepletion reactions affected the association of Cdk7
with other nuclear proteins, HeLa nuclear extract was sedimented
through a glycerol gradient containing either 0.1 M or 0.8 M KCl. The resultant gradient fractions were analyzed by immunoblotting with antibodies specific for Cdk7 of the CAK complex and ERCC3 of core-TFIIH (Fig. 3). In the presence of 0.8 M KCl,
Cdk7 was detected in fractions 4 to 6 with an estimated molecular mass
of ~100 kDa, which is similar to the calculated molecular mass (115 kDa) of the CAK ternary complex (Fig. 3A). Both cyclin H and Mat1 were
also detected in these fractions (data not shown), suggesting that CAK
is likely to be the predominant Cdk7-containing complex in nuclear
extract at this salt concentration. In contrast, when nuclear extract was analyzed in a glycerol gradient containing 0.1 M KCl, Cdk7 was
detected in many fractions (Fig. 3B), suggesting that it may be present
in several different complexes, including the CAK complex. Approximately 10% of Cdk7 was found in fraction 11, corresponding to a
molecular mass of ~465 kDa, which is similar to the calculated molecular mass (~510 kDa) of the holo-TFIIH complex. These
experiments demonstrate that while the association of Cdk7 with cyclin
H and Mat1 in the CAK complex was stable in the presence of 0.8 M KCl, the interaction of Cdk7-CAK with other nuclear proteins was disrupted by a high salt concentration.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 3.
Cdk7-containing complexes have different sizes at
different salt concentrations. HeLa nuclear extracts were subjected to
ultracentrifugation sedimentation through a 13 to 30% glycerol
gradient containing either 0.1 M (B and D) or 0.8 M KCl (A and C).
Gradient fractions were analyzed by Western blotting using antibodies
specific for Cdk7 (A and B) or ERCC3 (C and D). A mixture of molecular
mass marker proteins were sedimented in a parallel gradient. Their
positions in the gradient were determined by SDS-PAGE and silver
staining and are indicated in between panels B and C.
|
|
We also examined the effect of different salt concentrations on the
distribution of ERCC3, a core-TFIIH subunit, in glycerol gradient
fractions. In the presence of 0.8 M KCl, most of ERCC3 was found in a
complex of ~250 kDa (Fig. 3C). In the presence of 0.1 M KCl, however,
~50% of ERCC3 was found in fractions 11 and 12 with an apparent
molecular mass similar to that of holo-TFIIH (Fig. 3D). About half of
ERCC3 was also found at the bottom of the centrifuge tube in protein
complexes or aggregates with very high molecular masses (Fig. 3D).
Therefore, like Cdk7-containing complexes, an increase in salt
concentration also decreased the size of ERCC3-containing complexes in
HeLa nuclear extract.
CAK can be efficiently removed from holo-TFIIH by anti-Cdk7
immunodepletion in the presence of high salt concentrations.
The above experiment revealed salt-sensitive interactions of Cdk7-CAK
and ERCC3 with HeLa nuclear proteins. When a partially purified TFIIH
fraction was loaded onto a glycerol gradient containing 1 M KCl, the
peak fractions of CAK and core-TFIIH were found to be partially
separated from each other (1). Although this may suggest a
high-salt-concentration-mediated disruption of the interaction of CAK
with core-TFIIH, it is also possible that the partially purified TFIIH
fraction was contaminated with some free CAK or that the process of
column fractionations, including a hydrophobic column, caused a
partial dissociation of CAK from core-TFIIH. To confirm the
salt-sensitive nature of the interaction between CAK and core-TFIIH, we
transfected human 293T cells with a construct expressing Cdk7-HA and
immunoprecipitated Cdk7-HA and its associated proteins from cell
lysates with MAb 12CA5 under two different salt concentrations (0.15 M
or 0.5 M NaCl). The immunoprecipitates were analyzed by Western
blotting with antibodies specific for ERCC3 and the three subunits of
CAK (Fig. 4A). At both salt
concentrations, MAb 12CA5 efficiently precipitated Cdk7-HA and
associated cyclin H and Mat1 in the CAK complex (Fig. 4A, lanes 3 and
4), whereas a control anti-Myc column did not precipitate these
proteins (lanes 1 and 2). Importantly, while 0.5 M NaCl had no effect
on the composition of the CAK ternary complex, it significantly reduced
the association of ERCC3-core-TFIIH with CAK (Fig. 4A, lane 4).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 4.
Efficient removal of CAK from holo-TFIIH by anti-Cdk7
depletion in the presence of high salt concentrations. (A) CAK can be
dissociated from holo-TFIIH by high salt concentrations. Human 293T
cells transiently transfected with an HA-tagged Cdk7 (Cdk7-HA)
construct were lysed with buffers containing either 500 mM or 150 mM
NaCl. Immunoprecipitation with anti-HA tag MAb 12CA5 was carried out at
the same salt concentrations as in the lysis buffers. The
immunoprecipitated proteins were analyzed by Western blotting with
antibodies directed against Cdk7, Mat1, cyclin H, and ERCC3 as
indicated. Occasionally, Cdk7-HA can be seen as a doublet probably
because it can be modified differently under different conditions. (B)
Cdk7-CAK in highly purified TFIIH complex can be immunodepleted in the
presence of high salt concentrations. Highly purified TFIIH preparation
was incubated with immobilized Cdk7 antibodies in the presence of 0.8 M
KCl. Western blotting with antibodies directed against Cdk7 and ERCC3
was carried out to examine the presence of these two proteins in the
highly purified TFIIH preparation after immunodepletion.
|
|
While the majority of CAK was separated from core-TFIIH by 0.5 M NaCl,
a small fraction of CAK appeared to interact with core-TFIIH in a
salt-resistant manner (Fig. 4A, lane 4). Furthermore, a TFIIH fraction
(30) purified extensively from HeLa nuclear extract by
multiple column chromatography steps, a few of which involved relatively high-salt conditions, also contained some cdk7-CAK (Fig. 4B,
lane 1). We were concerned with the possibility that perhaps a small
fraction of holo-TFIIH with tightly bound CAK was somehow resistant to
anti-Cdk7 immunodepletion and was fully responsible for the
transcriptional activity observed in Fig. 2B. To examine this
possibility, we subjected a highly purified TFIIH preparation (kindly
provided by Jae-sang Kim and Phillip Sharp) (30) to
anti-Cdk7 immunodepletion under the same high-salt condition (0.8 M
KCl) used for the depletion of HeLa nuclear extract (Fig. 2B). Western
blotting indicated that while Cdk7 was efficiently removed from this
fraction, the core-TFIIH subunit ERCC3 was left behind (Fig. 4B). This,
together with the previous results, indicated that CAK can be
dissociated from core-TFIIH and quantitatively removed from HeLa
nuclear extract by a combination of anti-Cdk7 immunodepletion and
high-salt-concentration treatment. Importantly, the CAK-free core-TFIIH
appeared to be fully active in mediating both basal and Tat-activated
HIV-1 transcription (Fig. 2B).
In contrast to depletion in the presence of high concentrations of
salt, depletion of Cdk7-CAK in 0.1 M KCl probably also removed
associated core-TFIIH, which resulted in a major loss of basal
transcription and an elimination of Tat transactivation (Fig. 2C). The
low-level, apparently TFIIH-independent transcription in the depleted
reaction may derive from a previously observed minor form of
transcription complex specified by the HIV-1 long terminal repeat that
is not regulated by Tat and does not need a TATA box for the assembly
(18). This form of complex may even lack a few other
"basal" factors, as Parvin and Sharp (29) have noticed
that basal transcription can proceed from some promoters and under
certain conditions in the absence of several "basal" factors such
as TFIIE, TFIIH, and TFIIA. Nevertheless, it is important to stress
that although the data in Fig. 2C revealed the importance of core-TFIIH
as a general transcription factor in basal and Tat-activated transcription, it provided no evidence in support of a Tat-specific role of core-TFIIH.
Removal of CAK from holo-TFIIH with anti-Mat1 antibodies does not
affect Tat transactivation.
Mat1 has been shown to be an integral
part of the CAK ternary complex and it can stabilize CAK and enhance
Cdk7 kinase activity (1, 8). Recently, it was reported that
anti-Mat1 antibodies inhibited Tat function in transcription reactions
in vitro (9). To further investigate the role of Mat1 in Tat
activation of HIV transcription, we subjected HeLa nuclear extract to
anti-Mat1 immunodepletion in the presence of 0.8 M KCl and examined the ability of the Mat1-depleted extract to mediate Tat activation. Western
blotting results shown in Fig. 5B
indicate a quantitative removal of both Mat1 and Cdk7 from HeLa nuclear
extract after depletion. Importantly, just like the Cdk7-depleted
extract, Mat1-depleted nuclear extract was also capable of supporting
both basal HIV-1 transcription and Tat transactivation (Fig. 5A; lanes
1 and 2 showed 3.6-fold and lanes 3 and 4 showed 4.1-fold Tat
activation when normalized to internal controls). Therefore, using
antibodies directed against two different subunits of CAK, our data
strongly argue that CAK, either free or associated with core-TFIIH, was dispensable for basal HIV-1 transcription elongation as well as Tat
transactivation in vitro.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Immunodepletion of CAK from holo-TFIIH with anti-Mat1
antibodies does not affect Tat activation. Immobilized anti-Mat1
antibodies were used to immunodeplete Mat1 from HeLa nuclear extract
containing 0.8 M KCl. Immobilized anti-Myc MAb was used in a control
depletion reaction. (A) The depleted extracts were analyzed for their
abilities to mediate Tat activation in transcription reactions as
described in the legend for Fig. 1. (B) The removal of Mat1 and its
associated Cdk7 in the CAK complex was confirmed by Western blotting
with anti-Mat1 and anti-Cdk7 antibodies.
|
|
 |
DISCUSSION |
Contrary to several recent reports suggesting an important role
for CAK in Tat activation of HIV-1 transcription, we show here that
while core-TFIIH subunits are essential for transcription, neither free
CAK ternary complex nor CAK associated with core-TFIIH appeared to be
required for basal and Tat-activated HIV-1 transcription. In contrast,
the human P-TEFb kinase complex was shown to be essential for both
processes. Complementing the functional studies of CAK, our data
indicated that under the conditions in which a specific and efficient
interaction is observed between Tat and P-TEFb, only weak interactions
between Tat and CAK and between Tat and core-TFIIH that are independent
of several critical amino acid residues in the Tat transactivation
domain can be detected.
A requirement for CAK in Tat transactivation was demonstrated
mainly by inhibiting CAK activity using kinase inhibitors such as
DRB and H-8 (9, 28), a Cdk7
pseudosubstrate peptide derived from a mutant Cdk2
(6), or anti-Mat1 antibodies (9). However, both
kinase inhibitors and the Cdk7 pseudosubstrate peptide
could potentially block Tat transactivation through inhibiting the
activity of other related kinases important for Tat function. For
example, the kinase activity of Cdk9, which interacts with cyclin T1 to form the P-TEFb complex, has been shown to be essential for Tat activation of HIV-1 transcriptional elongation (42). In
kinase reactions, phosphorylation of pol II CTD by P-TEFb was found to be more sensitive to DRB inhibition than phosphorylation by Cdk7-CAK of
holo-TFIIH (21). In fact, the inhibition profile of a group of kinase inhibitors on the activity of Cdk9-P-TEFb, but not on Cdk7-TFIIH, correlated very well with their abilities to block Tat
function (21). Given the fact that both Cdk7 and Cdk9
belong to the same Cdk kinase superfamily, it is possible that the
kinase activity of Cdk9 was also inhibited when excess amounts of a
pseudosubstrate inhibitor of Cdk7 (a Cdk2 substrate peptide
containing a point mutation at Thr-160) was used to block Tat
activation (6). In addition to the kinase inhibitors and
pseudosubstrate peptide, HIV-1 transcription and Tat
transactivation were also found to be inhibited by Mat1 antibodies
(9). Similarly, antibodies against the other subunits of CAK
(Cdk7 and cyclin H) were shown to inhibit basal transcription from
certain promoters in vivo and in vitro (2, 34, 36). This
inhibition is difficult to interpret, as it could be due to either
sequestration of CAK kinase activity, disruption of the holo-TFIIH
complex, or sterically blocking the critical enzymatic activities of
the core-TFIIH subunits by the antibodies.
The role of CAK in TFIIH-mediated transcription remains controversial.
In yeast, Cdk7 kinase activity is encoded by an essential gene called
KIN28. Recently, a set of genes have been shown to require neither
KIN28 kinase nor normally critical components of the RNA polymerase II
holoenzyme for their activated transcription (15, 25). In
reconstituted transcription reactions in vitro, Cdk7 kinase activity is
required for transcription from the murine dihydrofolate reductase
promoter (2), but is completely dispensable for both
basal and activated transcription from the adenovirus major late
promoter (2, 19). Based on these studies, it has been
proposed that transcription from various pol II promoters is
accomplished by different mechanisms and the Cdk7-CAK kinase associated with core-TFIIH may contribute to transcription in a
promoter- or transactivator-specific manner (15, 25).
Unlike many DNA sequence-specific transcription factors which
activate transcription primarily by increasing the rate of
initiation, Tat interacts with the nascent TAR RNA stem-loop structure
and enhances HIV-1 transcription by stimulating the efficiency of elongation by RNA polymerase II (12, 13). It has been shown that activation of transcription initiation by Gal4-VP16 from the
adenovirus major late promoter can be mediated by a mutant TFIIH with a
kinase-inactive Cdk7 subunit (19). As an important extension
of this earlier observation, we show here that stimulation of
polymerase elongation by Tat in vitro can also be mediated by
core-TFIIH free of Cdk7-CAK. However, our data cannot rule out an
indirect role of CAK in phosphorylating and activating certain critical
transcription factors (e.g., P-TEFb), whose modification may be
essential for Tat function in vivo. The requirement for CAK in
transcription reactions in vitro is eliminated probably because these
critical transcription factors are already in an activated state when
isolated from the cell.
Hyperphosphorylation of polymerase CTD has been implicated in the
generation of highly processive polymerase elongation complexes (7). Consistent with this notion, Tat activation of HIV-1
elongation has been shown to require CTD (5, 26, 28, 39),
although there has yet to be a direct demonstration of a Tat-dependent increase of CTD phosphorylation during transcription. In in vitro kinase reactions, CTD has been shown to be an excellent substrate for
many cellular kinases, including several Cdk kinases, such as Cdk7 of
CAK-TFIIH, Cdk8 of the SRB-mediator complex, and Cdk9 of P-TEFb
(17, 23, 35, 36). Whether these different kinases also
phosphorylate CTD during transcription and how they may affect transcription at different stages of the transcription cycle remain largely unknown. Our results suggest that phosphorylation of
CTD and perhaps other components of the transcriptional machinery by
Cdk7-TFIIH is not essential for Tat activation of HIV-1 transcription in vitro. It remains to be tested whether other related kinases in
Cdk7-depleted nuclear extract can functionally replace the Cdk7-TFIIH
kinase activity and mediate Tat transactivation. Future studies may
reveal other functional substrates of the Cdk7-TFIIH kinase and help us
understand the mechanism by which this kinase affects transcription in
a promoter- or transactivator-specific fashion.
 |
ACKNOWLEDGMENTS |
We thank M. Peterlin and T. Cujec for the Cdk7-HA constructs, J. Kim and P. A. Sharp for a highly purified TFIIH fraction, and A. Rice for Tat mutant constructs. We thank B. O'Keeffe, K. Luo, and R. Tjian for valuable comments on the manuscript.
This work was supported by grants from the National Institutes of
Health (AI-41757) and the University of California Universitywide AIDS
Research Program (R97-B-113) to Q.Z.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: 206 Stanley
Hall, #3206, University of California, Berkeley, Berkeley, CA 94720. Phone: (510) 643-1697. Fax: (510) 643-9290. E-mail:
qzhou{at}uclink4.berkeley.edu.
 |
REFERENCES |
| 1.
|
Adamczewski, J. P.,
M. Rossignol,
J. P. Tassan,
E. A. Nigg,
V. Moncollin, and J. M. Egly.
1996.
MAT1, cdk7 and cyclin H form a kinase complex which is UV light-sensitive upon association with TFIIH.
EMBO J.
15:1877-1884[Medline].
|
| 2.
|
Akoulitchev, S.,
T. P. Makela,
R. A. Weinberg, and D. Reinberg.
1995.
Requirement for TFIIH kinase activity in transcription by RNA polymerase II.
Nature
377:557-560[Medline].
|
| 3.
|
Blau, J.,
H. Xiao,
S. McCracken,
P. O'Hare,
J. Greenblatt, and D. Bentley.
1996.
Three functional classes of transcriptional activation domain.
Mol. Cell. Biol.
16:2044-2055[Abstract].
|
| 4.
| Chen, D., Y. Fong, and Q. Zhou. Specific
interaction of Tat with the human but not rodent P-TEFb complex
mediates the species-specific Tat activation of HIV-1 transcription.
Proc. Natl. Acad. Sci. USA, in press.
|
| 5.
|
Chun, R. F., and K. T. Jeang.
1996.
Requirements for RNA polymerase II carboxyl-terminal domain for activated transcription of human retroviruses human T-cell lymphotropic virus I and HIV-1.
J. Biol. Chem.
271:27888-27894[Abstract/Free Full Text].
|
| 6.
|
Cujec, T. P.,
H. Okamoto,
K. Fujinaga,
J. Meyer,
H. Chamberlin,
D. O. Morgan, and B. M. Peterlin.
1997.
The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II.
Genes Dev.
11:2645-2657[Abstract/Free Full Text].
|
| 7.
|
Dahmus, M. E.
1996.
Reversible phosphorylation of the C-terminal domain of RNA polymerase II.
J. Biol. Chem.
271:19009-19012[Free Full Text].
|
| 8.
|
Fisher, R. P.,
P. Jin,
H. M. Chamberlin, and D. O. Morgan.
1995.
Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase.
Cell
83:47-57[Medline].
|
| 9.
|
Garcia-Martinez, L. F.,
G. Mavankal,
J. M. Neveu,
W. S. Lane,
D. Ivanov, and R. B. Gaynor.
1997.
Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription.
EMBO J.
16:2836-2850[Medline].
|
| 10.
|
Harlow, E., and D. Lane.
1988.
Antibodies: a laboratory manual.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 11.
|
Herrmann, C. H., and A. P. Rice.
1995.
Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor.
J. Virol.
69:1612-1620[Abstract].
|
| 12.
|
Jones, K. A.
1997.
Taking a new TAK on Tat transactivation.
Genes Dev.
11:2593-2599[Free Full Text].
|
| 13.
|
Jones, K. A., and B. M. Peterlin.
1994.
Control of RNA initiation and elongation at the HIV-1 promoter.
Annu. Rev. Biochem.
63:717-743[Medline].
|
| 14.
|
Kephart, D. D.,
N. F. Marshall, and D. H. Price.
1992.
Stability of Drosophila RNA polymerase II elongation complexes in vitro.
Mol. Cell. Biol.
12:2067-2077[Abstract/Free Full Text].
|
| 15.
|
Lee, D., and J. T. Lis.
1998.
Transcriptional activation independent of TFIIH kinase and the RNA polymerase II mediator in vivo.
Nature
393:389-392[Medline].
|
| 16.
|
Li, X., and M. R. Green.
1998.
The HIV-1 Tat cellular coactivator Tat-SF1 is a general transcription elongation factor.
Genes Dev.
12:2992-2996[Abstract/Free Full Text].
|
| 17.
|
Liao, S. M.,
J. Zhang,
D. A. Jeffery,
A. J. Koleske,
C. M. Thompson,
D. M. Chao,
M. Viljoen,
H. J. van Vuuren, and R. A. Young.
1995.
A kinase-cyclin pair in the RNA polymerase II holoenzyme.
Nature
374:193-196[Medline].
|
| 18.
|
Lu, X.,
T. M. Welsh, and B. M. Peterlin.
1993.
The human immunodeficiency virus type 1 long terminal repeat specifies two different transcription complexes, only one of which is regulated by Tat.
J. Virol.
67:1752-1760[Abstract/Free Full Text].
|
| 19.
|
Makela, T. P.,
J. D. Parvin,
J. Kim,
L. J. Huber,
P. A. Sharp, and R. A. Weinberg.
1995.
A kinase-deficient transcription factor TFIIH is functional in basal and activated transcription.
Proc. Natl. Acad. Sci. USA
92:5174-5178[Abstract/Free Full Text].
|
| 20.
|
Maldonado, E., and D. Reinberg.
1995.
News on initiation and elongation of transcription by RNA polymerase II.
Curr. Opin. Cell Biol.
7:352-361[Medline].
|
| 21.
|
Mancebo, H. S.,
G. Lee,
J. Flygare,
J. Tomassini,
P. Luu,
Y. Zhu,
J. Peng,
C. Blau,
D. Hazuda,
D. Price, and O. Flores.
1997.
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro.
Genes Dev.
11:2633-2644[Abstract/Free Full Text].
|
| 22.
|
Marciniak, R. A., and P. A. Sharp.
1991.
HIV-1 Tat protein promotes formation of more-processive elongation complexes.
EMBO J.
10:4189-4196[Medline].
|
| 23.
|
Marshall, N. F.,
J. Peng,
Z. Xie, and D. H. Price.
1996.
Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase.
J. Biol. Chem.
271:27176-27183[Abstract/Free Full Text].
|
| 24.
|
Marshall, N. F., and D. H. Price.
1995.
Purification of P-TEFb, a transcription factor required for the transition into productive elongation.
J. Biol. Chem.
270:12335-12338[Abstract/Free Full Text].
|
| 25.
|
McNeil, J.,
H. Agah, and D. Bentley.
1998.
Activated transcription independent of the RNA polymerase II holoenzyme in budding yeast.
Genes Dev.
12:2510-2521[Abstract/Free Full Text].
|
| 26.
|
Okamoto, H.,
C. T. Sheline,
J. L. Corden,
K. A. Jones, and B. M. Peterlin.
1996.
Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II.
Proc. Natl. Acad. Sci. USA
93:11575-11579[Abstract/Free Full Text].
|
| 27.
| O'Keeffe, B., Y. Fong, D. Chen, and Q. Zhou.
Requirement for a kinase-specific chaperone pathway in the production
of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated Tat
stimulation of HIV-1 transcription. Submitted for publication.
|
| 28.
|
Parada, C. A., and R. G. Roeder.
1996.
Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain.
Nature
384:375-378[Medline].
|
| 29.
|
Parvin, J. D., and P. A. Sharp.
1993.
DNA topology and a minimal set of basal factors for transcription by RNA polymerase II.
Cell
73:533-540[Medline].
|
| 30.
|
Parvin, J. D.,
B. M. Shykind,
R. E. Meyers,
J. Kim, and P. A. Sharp.
1994.
Multiple sets of basal factors initiate transcription by RNA polymerase II.
J. Biol. Chem.
269:18414-18421[Abstract/Free Full Text].
|
| 31.
|
Parvin, J. D.,
H. T. Timmers, and P. A. Sharp.
1992.
Promoter specificity of basal transcription factors.
Cell
68:1135-1144[Medline].
|
| 32.
|
Peng, J.,
Y. Zhu,
J. T. Milton, and D. H. Price.
1998.
Identification of multiple cyclin subunits of human P-TEFb.
Genes Dev.
12:755-762[Abstract/Free Full Text].
|
| 33.
|
Rice, A. P., and F. Carlotti.
1990.
Structural analysis of wild-type and mutant human immunodeficiency virus type 1 Tat proteins.
J. Virol.
64:6018-6026[Abstract/Free Full Text].
|
| 34.
|
Roy, R.,
J. P. Adamczewski,
T. Seroz,
W. Vermeulen,
J. P. Tassan,
L. Schaeffer,
E. A. Nigg,
J. H. Hoeijmakers, and J. M. Egly.
1994.
The MO15 cell cycle kinase is associated with the TFIIH transcription-DNA repair factor.
Cell
79:1093-1101[Medline].
|
| 35.
|
Serizawa, H.,
T. P. Makela,
J. W. Conaway,
R. C. Conaway,
R. A. Weinberg, and R. A. Young.
1995.
Association of Cdk-activating kinase subunits with transcription factor TFIIH.
Nature
374:280-282[Medline].
|
| 36.
|
Shiekhattar, R.,
F. Mermelstein,
R. P. Fisher,
R. Drapkin,
B. Dynlacht,
H. C. Wessling,
D. O. Morgan, and D. Reinberg.
1995.
Cdk-activating kinase complex is a component of human transcription factor TFIIH.
Nature
374:283-287[Medline].
|
| 37.
|
Svejstrup, J. Q.,
P. Vichi, and J. M. Egly.
1996.
The multiple roles of transcription/repair factor TFIIH.
Trends Biochem. Sci.
21:346-350[Medline].
|
| 38.
|
Wei, P.,
M. E. Garber,
S. M. Fang,
W. H. Fischer, and K. A. Jones.
1998.
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.
Cell
92:451-462[Medline].
|
| 39.
|
Yang, X.,
C. H. Herrmann, and A. P. Rice.
1996.
The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function.
J. Virol.
70:4576-4584[Abstract].
|
| 40.
|
Yankulov, K., and D. Bentley.
1998.
Transcriptional control: Tat cofactors and transcriptional elongation.
Curr. Biol.
8:447-449.
|
| 41.
|
Zawel, L.,
K. P. Kumar, and D. Reinberg.
1995.
Recycling of the general transcription factors during RNA polymerase II transcription.
Genes Dev.
9:1479-1490[Abstract/Free Full Text].
|
| 42.
|
Zhou, Q.,
D. Chen,
E. Pierstorff, and K. Luo.
1998.
Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages.
EMBO J.
17:3681-3691[Medline].
|
| 43.
|
Zhou, Q.,
P. M. Lieberman,
T. G. Boyer, and A. J. Berk.
1992.
Holo-TFIID supports transcriptional stimulation by diverse activators and from a TATA-less promoter.
Genes Dev.
6:1964-1974[Abstract/Free Full Text].
|
| 44.
|
Zhou, Q., and P. A. Sharp.
1995.
Novel mechanism and factor for regulation by HIV-1 Tat.
EMBO J.
14:321-328[Medline].
|
| 45.
|
Zhu, Y.,
T. Pe'ery,
J. Peng,
Y. Ramanathan,
N. Marshall,
T. Marshall,
B. Amendt,
M. B. Mathews, and D. H. Price.
1997.
Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro.
Genes Dev.
11:2622-2632[Abstract/Free Full Text].
|
Molecular and Cellular Biology, April 1999, p. 2863-2871, Vol. 19, No. 4
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zanton, S. J., Pugh, B. F.
(2006). Full and partial genome-wide assembly and disassembly of the yeast transcription machinery in response to heat shock.. Genes Dev.
20: 2250-2265
[Abstract]
[Full Text]
-
Pei, Y., Du, H., Singer, J., St. Amour, C., Granitto, S., Shuman, S., Fisher, R. P.
(2006). Cyclin-Dependent Kinase 9 (Cdk9) of Fission Yeast Is Activated by the CDK-Activating Kinase Csk1, Overlaps Functionally with the TFIIH-Associated Kinase Mcs6, and Associates with the mRNA Cap Methyltransferase Pcm1 In Vivo. Mol. Cell. Biol.
26: 777-788
[Abstract]
[Full Text]
-
Fisher, R. P.
(2005). Secrets of a double agent: CDK7 in cell-cycle control and transcription. J. Cell Sci.
118: 5171-5180
[Abstract]
[Full Text]
-
Bres, V., Gomes, N., Pickle, L., Jones, K. A.
(2005). A human splicing factor, SKIP, associates with P-TEFb and enhances transcription elongation by HIV-1 Tat. Genes Dev.
19: 1211-1226
[Abstract]
[Full Text]
-
Zhou, M., Deng, L., Lacoste, V., Park, H. U., Pumfery, A., Kashanchi, F., Brady, J. N., Kumar, A.
(2004). Coordination of Transcription Factor Phosphorylation and Histone Methylation by the P-TEFb Kinase during Human Immunodeficiency Virus Type 1 Transcription. J. Virol.
78: 13522-13533
[Abstract]
[Full Text]
-
Zhou, M., Deng, L., Kashanchi, F., Brady, J. N., Shatkin, A. J., Kumar, A.
(2003). The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA. Proc. Natl. Acad. Sci. USA
100: 12666-12671
[Abstract]
[Full Text]
-
Schwartz, B. E., Larochelle, S., Suter, B., Lis, J. T.
(2003). Cdk7 Is Required for Full Activation of Drosophila Heat Shock Genes and RNA Polymerase II Phosphorylation In Vivo. Mol. Cell. Biol.
23: 6876-6886
[Abstract]
[Full Text]
-
Yedavalli, V. S. R. K., Benkirane, M., Jeang, K.-T.
(2003). Tat and Trans-activation-responsive (TAR) RNA-independent Induction of HIV-1 Long Terminal Repeat by Human and Murine Cyclin T1 Requires Sp1. J. Biol. Chem.
278: 6404-6410
[Abstract]
[Full Text]
-
Shim, E. Y., Walker, A. K., Shi, Y., Blackwell, T. K.
(2002). CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo. Genes Dev.
16: 2135-2146
[Abstract]
[Full Text]
-
Kim, Y. K., Bourgeois, C. F., Isel, C., Churcher, M. J., Karn, J.
(2002). Phosphorylation of the RNA Polymerase II Carboxyl-Terminal Domain by CDK9 Is Directly Responsible for Human Immunodeficiency Virus Type 1 Tat-Activated Transcriptional Elongation. Mol. Cell. Biol.
22: 4622-4637
[Abstract]
[Full Text]
-
Bourgeois, C. F., Kim, Y. K., Churcher, M. J., West, M. J., Karn, J.
(2002). Spt5 Cooperates with Human Immunodeficiency Virus Type 1 Tat by Preventing Premature RNA Release at Terminator Sequences. Mol. Cell. Biol.
22: 1079-1093
[Abstract]
[Full Text]
-
Garber, M. E., Mayall, T. P., Suess, E. M., Meisenhelder, J., Thompson, N. E., Jones, K. A.
(2000). CDK9 Autophosphorylation Regulates High-Affinity Binding of the Human Immunodeficiency Virus Type 1 Tat-P-TEFb Complex to TAR RNA. Mol. Cell. Biol.
20: 6958-6969
[Abstract]
[Full Text]
-
Zhou, M., Halanski, M. A., Radonovich, M. F., Kashanchi, F., Peng, J., Price, D. H., Brady, J. N.
(2000). Tat Modifies the Activity of CDK9 To Phosphorylate Serine 5 of the RNA Polymerase II Carboxyl-Terminal Domain during Human Immunodeficiency Virus Type 1 Transcription. Mol. Cell. Biol.
20: 5077-5086
[Abstract]
[Full Text]
-
Price, D. H.
(2000). P-TEFb, a Cyclin-Dependent Kinase Controlling Elongation by RNA Polymerase II. Mol. Cell. Biol.
20: 2629-2634
[Full Text]
-
O'Keeffe, B., Fong, Y., Chen, D., Zhou, S., Zhou, Q.
(2000). Requirement for a Kinase-specific Chaperone Pathway in the Production of a Cdk9/Cyclin T1 Heterodimer Responsible for P-TEFb-mediated Tat Stimulation of HIV-1 Transcription. J. Biol. Chem.
275: 279-287
[Abstract]
[Full Text]
-
Jeang, K.-T., Xiao, H., Rich, E. A.
(1999). Multifaceted Activities of the HIV-1 Transactivator of Transcription, Tat. J. Biol. Chem.
274: 28837-28840
[Full Text]
-
Marshall, N. F., Dahmus, M. E.
(2000). C-terminal Domain Phosphatase Sensitivity of RNA Polymerase II in Early Elongation Complexes on the HIV-1 and Adenovirus 2 Major Late Templates. J. Biol. Chem.
275: 32430-32437
[Abstract]
[Full Text]
-
Kim, J. B., Sharp, P. A.
(2001). Positive Transcription Elongation Factor b Phosphorylates hSPT5 and RNA Polymerase II Carboxyl-terminal Domain Independently of Cyclin-dependent Kinase-activating Kinase. J. Biol. Chem.
276: 12317-12323
[Abstract]
[Full Text]
-
Ramanathan, Y., Rajpara, S. M., Reza, S. M., Lees, E., Shuman, S., Mathews, M. B., Pe'ery, T.
(2001). Three RNA Polymerase II Carboxyl-terminal Domain Kinases Display Distinct Substrate Preferences. J. Biol. Chem.
276: 10913-10920
[Abstract]
[Full Text]
-
Zhou, M., Nekhai, S., Bharucha, D. C., Kumar, A., Ge, H., Price, D. H., Egly, J.-M., Brady, J. N.
(2001). TFIIH Inhibits CDK9 Phosphorylation during Human Immunodeficiency Virus Type 1 Transcription. J. Biol. Chem.
276: 44633-44640
[Abstract]
[Full Text]